参考文献 References
[1] Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application [J]. Nat Immunol, 2013, 14(12): 1212-8.
[2] 政策法规司．中华人民共和国医师法：中华人民共和国主席令（第94号） [EB/OL]. (2021-08-20) [2022-04-18]. http://www.gov.cn/xinwen/2021-08/20/content_5632496.htm.
[3] 湖北省医院协会要是专业委员会《湖北省医疗机构药品拓展性临床应用管理专家共识》编写组．湖北省医疗机构药品拓展性临床应用管理专家共识 [J]. 医药导报.
[4] Xu N, Han B, Jiao S, et al. 31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma[J]. Annals of Oncology, 2020, 31: S1428-S9.
[5] Li B, Chan H L, Chen P. Immune Checkpoint Inhibitors: Basics and Challenges [J]. Curr Med Chem, 2019, 26(17): 3009-25.
[6] Sun C, Mezzadra R, Schumacher TN. Regulation andFunction of the PD-L1 Checkpoint [J]. Immunity, 2018, 48(3): 434-52.
[7] Zheng Y, Mislang ARA, Coward J, et al. Penpulimab,an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers [J]. Cancer Immunol Immunother, 2022.
[8] Han C, Ye S, Hu C, et al. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203) [J]. Front Oncol, 2021, 11: 684867.
[9] Jiao S.C., Bai L, Dong J. Clinical activity and safetyof penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC) [J]. Journal of Clinical Oncology, 2020, 38: 15.
[10] Paz-Ares, Luis, Ciuleanu, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (checkmate 9la): an international, randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 22(2): 198-211.
[11] Han B, Chen J, Wang Z. Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamousnonsmall-cell lung cancer [J]. Journal of Clinical Oncology, 2021, 39: 15 SUPPL
[12] Dhillon S. Penpulimab: First Approval [J]. Drugs, 2021, 81(18): 2159-66.
[13] Zhang C, Yang S, Chen J. Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy [J]. Journal of Clinical Oncology, 2021, 39: 15 SUPPL
[14] Shi Y.-K, Gao L, Tian Y. Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study [J]. Annals of Oncology, 2021, 32(S806): Supplement 5.
[15] Chen X, Hu C, Wang W. A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more linesof chemotherapy: Updated results [J]. Annals of Oncology, 2021, 32(S806): Supplement 5.
[16] Mislang A R A, Coward J, Cooper A, et al. 157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody,in upper gastrointestinal cancers [J]. Annals of Oncology, 2020, 31: S1300-S1.
[17] Zhou C, Chen G, Huang Y, et al. Camrelizumab pluscarboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Respir Med, 2021, 9(3): 305-314.
[18] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J]. N Engl J Med, 2016, 375 (19): 1856-1867.
[19] Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamouscell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J]. Lancet Oncol, 2017, 18 (8): 1104-1115
[20] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 withanalyses by tumor PD-L1 expression [J]. Oral Oncol, 2018, 81: 45-51.
[21] Fan Y, Zhao J, Wang Q, et al. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): a multicenter, two-stage, phase 2 Trial [J]. J Thorac Oncol, 2021, 16 (2): 299-309.
[22] Kim RD, Chung V, Alese OB, et al. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol, 2020, 6(6): 888-894.